
Feb 25 (Reuters) - Contract drug manufacturer Thermo Fisher Scientific TMO.N said on Tuesday it will buy Solventum's SOLV.N purification and filtration business for about $4.1 billion in cash.
The transaction is expected to be completed by the end of 2025.